STUDIES
ON
CYSTIC
FIBROSIS
USING
ISOELECTRIC
FOCUSING
I
AN
ASSAY
FOR
DETECTION
OF
CYSTIC
FIBROSIS
HOMOZYGOTES
AND
HETEROZYGOTE
CARRIERS
FROM
SERUM
WE
HAVE
DEVELOPED
A
STANDARDIZED
BIOPHYSICAL
ASSAY
FOR
THE
RAPID
DETECTION
OF
INDIVIDUALS
HOMOZYGOUS
OR
HETEROZYGOUS
FOR
CYSTIC
FIBROSIS
CF
THE
ASSAY
EMPLOYS
ISOELECTRIC
FOCUSING
IN
THIN
LAYER
POLYACRYLAMIDE
GELS
TO
ANALYZE
MICROLITER
QUANTITIES
OF
WHOLE
SERUM
FOR
THE
PRESENCE
OF
A
CF
FACTOR
PROTEIN
AND
FOR
DELETIONS
IN
A
GROUP
OF
PROTEINS
CALLED
PROTEINS
B
C
AND
D
FIG
1
A
PH
510
GRADIENT
IS
USED
FIG
2
AND
EACH
SAMPLE
IS
SCREENED
USING
A
SERUM
VOLUME
WHICH
CONTAINS
300
G
IMMUNOGLOBULIN
G
IGG
INDIVIDUALS
HOMOZYGOUS
OR
HETEROZYGOUS
FOR
CF
ARE
DISTINGUISHED
FROM
NORMAL
UNAFFECTED
INDIVIDUALS
ON
THE
BASIS
OF
THE
PRESENCE
OF
A
CF
FACTOR
PROTEIN
BAND
TABLE
1
HETEROZYGOUS
CARRIERS
FOR
CF
ARE
DISTINGUISHED
FROM
CF
HOMOZYGOTES
75
PERCENT
OF
THE
TIME
ON
THE
BASIS
OF
A
DELETION
IN
EITHER
BAND
B
C
OR
D
TABLE
2
ON
THE
BASIS
OF
SCREENING
65
PATIENTS
WITH
CYSTIC
FIBROSIS
61
HETEROZYGOUS
CARRIERS
FOR
CF
AND
105
NORMAL
CONTROL
SUBJECTS
IT
WAS
CONCLUDED
THAT
NO
OBVIOUS
CORRELATION
EXISTED
BETWEEN
EITHER
SEX
AGE
OR
SEVERITY
OF
THE
DISEASE
IN
THE
INDIVIDUAL
CF
PATIENT
AND
THE
ABSOLUTE
PRESENCE
OR
ABSENCE
OF
THE
CF
FACTOR
IN
ADDITION
NO
CORRELATION
EXISTED
BETWEEN
SEX
OR
AGE
AND
THE
PRESENCE
OF
THE
CF
FACTOR
OR
DELETIONS
IN
PROTEINS
B
C
AND
D
IN
THE
INDIVIDUAL
HETEROZYGOUS
CARRIER
FOR
CF
OR
NORMAL
CONTROL
SUBJECTS
ANALYSIS
OF
SERUM
SAMPLES
FROM
68
PATIENTS
WITH
A
VARIETY
OF
OTHER
DISEASES
MANY
WITH
CLINICAL
SYMPTOMS
RESEMBLING
THOSE
SEEN
IN
THE
PATIENT
WITH
CYSTIC
FIBROSIS
TABLE
3
INDICATED
THAT
THE
CF
FACTOR
PROTEIN
DESCRIBED
IN
THIS
STUDY
APPEARS
TO
BE
DIAGNOSTIC
FOR
CF
GENOTYPES
WITH
THE
POSSIBLE
EXCEPTION
OF
PATIENTS
WITH
CERTAIN
TYPES
OF
LEUKEMIA
